Compare · BIIB vs SOPH
BIIB vs SOPH
Side-by-side comparison of Biogen Inc. (BIIB) and SOPHiA GENETICS SA (SOPH): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BIIB and SOPH operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- BIIB is the larger of the two at $32.62B, about 44.3x SOPH ($736.4M).
- SOPH has been more active in the news (14 items in the past 4 weeks vs 9 for BIIB).
- BIIB has more recent analyst coverage (25 ratings vs 14 for SOPH).
- Company
- Biogen Inc.
- SOPHiA GENETICS SA
- Price
- $220.57+1.10%
- $8.64+2.49%
- Market cap
- $32.62B
- $736.4M
- 1M return
- -
- +53.19%
- 1Y return
- -
- +157.91%
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2021
- News (4w)
- 9
- 14
- Recent ratings
- 25
- 14
Biogen Inc.
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; and FLIXABI, an infliximab biosimilar referencing REMICADE. In addition, the company offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; and OCREVUS for treating relapsing MS and primary progressive MS; and other anti-CD20 therapies. Further, it develops BIIB061, BIIB091, and BIIB107 for MS and neuroimmunology; Aducanumab, BAN2401, BIIB092, BIIB076, and BIIB080 to treat Alzheimer's disease and dementia; BIIB067, BIIB078, BIIB105, BIIB100, and BIIB110 to treat neuromuscular disorders; BIIB124, BIIB094, BIIB118, BIIB101, and BIIB122 for treating Parkinson's disease and movement disorders; BIIB111 and BIIB112 to treat ophthalmology related diseases; BIIB125 and BIIB104 for treating neuropsychiatry; Dapirolizumab pegol and BIIB059 to treat immunology related diseases; BIIB093 and TMS-007 to treat acute neurology; BIIB074 and BIIB095 for neuropathic pain; and SB11 and SB15 biosimilars, which are under various stages of development. The company has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Bristol-Myers Squibb Company; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Ginkgo Bioworks; Capsigen Inc.; and Mirimus, Inc. Biogen Inc. was founded in 1978 and is headquartered in Cambridge, Massachusetts.
SOPHiA GENETICS SA
Sophia Genetics SA, a cloud-based software-as-a-service platform that enables healthcare institutions to get insights from their data. The company offers SOPHiA DDM for solid tumors. Sophia Genetics SA was founded in 2012 and is based in Saint-Sulpice, Switzerland.
Latest BIIB
- LEQEMBI IQLIK® (lecanemab-irmb) Autoinjector for Initiation of Therapy Now Available in the U.S. for Early Alzheimer’s Disease
- LEQEMBI IQLIK®(lecanemab-irmb) Autoinjector for Initiation of Therapy Now Available in the U.S. for Early Alzheimer's Disease
- Biogen upgraded by Wolfe Research with a new price target
- SEC Form 3 filed by new insider Parini Michael
- Biogen Completes Acquisition of RayThera Inc.
- Amendment: SEC Form SCHEDULE 13G/A filed by Biogen Inc.
- Director Minor Lloyd sold $239,750 worth of shares (1,186 units at $202.15), decreasing direct ownership by 31% to 2,689 units (SEC Form 4)
- Stoke Therapeutics to Present at the Canaccord Genuity 46th Annual Growth Conference
- Stoke Therapeutics Announces Second Quarter 2026 Financial Results and Provides Business Updates
- SEC Form 10-Q filed by Biogen Inc.
Latest SOPH
- SEC Form 144 filed by SOPHiA GENETICS SA
- Chief People Officer Valente Manuela exercised 10,000 units of Ordinary Shares at a strike of $3.20 and sold $79,439 worth of Ordinary Shares (10,000 units at $7.94) as part of a pre-agreed trading plan (SEC Form 4)
- Chief Scientific Officer Xu Zhenyu sold $163,482 worth of Ordinary Shares (20,000 units at $8.17) as part of a pre-agreed trading plan, decreasing direct ownership by 3% to 566,887 units (SEC Form 4)
- Chief Scientific Officer Xu Zhenyu sold $30,076 worth of Ordinary Shares (4,000 units at $7.52) as part of a pre-agreed trading plan, decreasing direct ownership by 0.68% to 586,887 units (SEC Form 4)
- Chief Medical Officer Menu Philippe sold $37,580 worth of Ordinary Shares (5,000 units at $7.52) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 218,387 units (SEC Form 4)
- Executive Chairman Camblong Jurgi sold $209,209 worth of Ordinary Shares (28,500 units at $7.34) as part of a pre-agreed trading plan, decreasing direct ownership by 0.82% to 3,444,322 units (SEC Form 4)
- Chief Technology Officer Verma Abhimanyu sold $38,000 worth of Ordinary Shares (5,000 units at $7.60) as part of a pre-agreed trading plan, decreasing direct ownership by 3% to 182,171 units (SEC Form 4)
- Chief Scientific Officer Xu Zhenyu exercised 10,000 units of Ordinary Shares at a strike of $3.28 and sold $144,924 worth of Ordinary Shares (20,000 units at $7.25) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 590,887 units (SEC Form 4)
- Executive Chairman Camblong Jurgi sold $138,412 worth of Ordinary Shares (20,000 units at $6.92) as part of a pre-agreed trading plan, decreasing direct ownership by 0.57% to 3,472,822 units (SEC Form 4)
- Chief Scientific Officer Xu Zhenyu sold $69,168 worth of Ordinary Shares (10,000 units at $6.92) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 600,887 units (SEC Form 4)